AU2003298514A1 - Methods and compositions using cholinesterase inhibitors - Google Patents

Methods and compositions using cholinesterase inhibitors

Info

Publication number
AU2003298514A1
AU2003298514A1 AU2003298514A AU2003298514A AU2003298514A1 AU 2003298514 A1 AU2003298514 A1 AU 2003298514A1 AU 2003298514 A AU2003298514 A AU 2003298514A AU 2003298514 A AU2003298514 A AU 2003298514A AU 2003298514 A1 AU2003298514 A1 AU 2003298514A1
Authority
AU
Australia
Prior art keywords
compositions
methods
cholinesterase inhibitors
cholinesterase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003298514A
Other versions
AU2003298514A8 (en
Inventor
John Ieni
Raymond Pratt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US38085202P priority Critical
Priority to US60/380,852 priority
Priority to US44772403P priority
Priority to US60/447,724 priority
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to PCT/US2003/015279 priority patent/WO2004034963A2/en
Publication of AU2003298514A8 publication Critical patent/AU2003298514A8/en
Publication of AU2003298514A1 publication Critical patent/AU2003298514A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/15Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
AU2003298514A 2002-05-17 2003-05-16 Methods and compositions using cholinesterase inhibitors Abandoned AU2003298514A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US38085202P true 2002-05-17 2002-05-17
US60/380,852 2002-05-17
US44772403P true 2003-02-19 2003-02-19
US60/447,724 2003-02-19
PCT/US2003/015279 WO2004034963A2 (en) 2002-05-17 2003-05-16 Methods and compositions using cholinesterase inhibitors

Publications (2)

Publication Number Publication Date
AU2003298514A8 AU2003298514A8 (en) 2004-05-04
AU2003298514A1 true AU2003298514A1 (en) 2004-05-04

Family

ID=32109967

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003298514A Abandoned AU2003298514A1 (en) 2002-05-17 2003-05-16 Methods and compositions using cholinesterase inhibitors

Country Status (4)

Country Link
US (5) US20060018839A1 (en)
AU (1) AU2003298514A1 (en)
TW (1) TW200401649A (en)
WO (1) WO2004034963A2 (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124730T2 (en) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. New methods using cholinesteraseinhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
WO2004009026A2 (en) * 2002-07-22 2004-01-29 Duke University Cholinergic therapy for individuals with learning disabilities
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
AU2004233863B2 (en) 2003-04-24 2010-06-17 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
CA2525970C (en) * 2003-05-15 2011-03-22 Roskamp Research, Llc Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
ES2258760T3 (en) 2003-07-22 2006-09-01 Arena Pharmaceuticals, Inc. Derivatives of diaril and the urea of arileteroaril used as modulators of serotonine 5-ht2a receptor useful for profilaxis and the treatment of disorders to them associates.
US7297691B2 (en) 2003-08-13 2007-11-20 Janssen Pharmaceutica N.V. Treatment of sleep disorders with cholinesterase inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP1689704A2 (en) 2003-10-21 2006-08-16 CoLucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
US20080026081A1 (en) * 2003-11-21 2008-01-31 Axel Unterbeck Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate
US20050222123A1 (en) * 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
US20070129350A1 (en) * 2004-01-30 2007-06-07 Axonyx, Inc. Methods for treatment of diabetes
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1729761A4 (en) * 2004-03-05 2008-09-03 Eisai Co Ltd Cadasil treatment with cholinesterase inhibitors
WO2005099823A1 (en) * 2004-04-14 2005-10-27 Warner-Lambert Company Llc Therapeutic combination for treatment of alzheimers disease
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
CA2508585A1 (en) * 2004-06-01 2005-12-01 Axonyx, Inc. Transdermal delivery system for treatment of cognitive disorders
EP1604686A1 (en) * 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
DE102004029325A1 (en) * 2004-06-10 2006-01-05 Universität Leipzig Use of a medicament, comprising cholinesterase inhibitor (e.g. donepezil), for the treatment of behavior disturbances and/or disturbances of cognitive functions caused due to the fetal alcohol syndrome
WO2006004201A1 (en) * 2004-07-01 2006-01-12 Eisai R & D Management Co., Ltd. Nerve reveneration promoter
US20060135507A1 (en) * 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
JP2006077006A (en) * 2004-08-13 2006-03-23 Eisai Co Ltd Therapeutic agent against hyperactive bladder with age
US20060172992A1 (en) * 2004-08-13 2006-08-03 Eisai Co., Ltd. Therapeutic agent for overactive bladder resulting from cerebral infarction
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
KR20070097590A (en) 2005-01-25 2007-10-04 에픽스 델라웨어, 인코포레이티드 Substituted arylamine compounds and their use as 5-ht6 modulators
US20080138388A1 (en) * 2005-02-04 2008-06-12 Hisamitsu Pharmaceutical Co., Inc. Transdermal Absorption Patch
US20060183733A1 (en) * 2005-02-11 2006-08-17 Stephen Wills Treating microvasculature diseases with acetyl cholinesterase inhibitors
AU2006232517A1 (en) * 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
WO2007012154A1 (en) * 2005-07-27 2007-02-01 Carlos Henrique Horta Lima Pharmaceutical preparation containing an acetylcholinesterase ihibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties.
WO2007016793A1 (en) * 2005-08-11 2007-02-15 Universite De Montreal Galantamine as a neuroprotective drug for retinal ganglion cells
EP2275095A3 (en) * 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2658326C (en) * 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
WO2008006286A1 (en) * 2006-07-05 2008-01-17 Tianjin Hemay Bio-Tech Co. Ltd ANALGESIC 5, 9 - METHANOCYCLOOCTA (b) PYRIDIN - 2 (1H) - ONE DERIVATIVES, THEIR PREPARATION METHOD AND USE
AU2007269090A1 (en) * 2006-07-06 2008-01-10 Roskamp Research Llc Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
EP2076288A2 (en) * 2006-09-22 2009-07-08 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US7984714B2 (en) 2006-09-29 2011-07-26 Nellcor Puritan Bennett Llc Managing obstructive sleep apnea and/or snoring using local time released agents
TWI415845B (en) 2006-10-03 2013-11-21 Arena Pharm Inc Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US8097633B2 (en) 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US9034890B2 (en) * 2006-11-15 2015-05-19 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
CN101588802A (en) * 2006-12-01 2009-11-25 日东电工株式会社;卫材R&D管理有限公司 Skin adhesive preparation comprising stabilized donepezil
WO2008066184A1 (en) * 2006-12-01 2008-06-05 Nitto Denko Corporation Method for prevention of coloration in donepezil-containing skin adhesive preparation, and method for reducing the production of donepezil analogue in donepezil-containing skin adhesive preparation
US7860379B2 (en) * 2007-01-15 2010-12-28 Applied Materials, Inc. Temperature measurement and control of wafer support in thermal processing chamber
CA2677241A1 (en) 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
WO2008111590A2 (en) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
WO2008139984A1 (en) * 2007-04-26 2008-11-20 Eisai R & D Management Co., Ltd. Cinnamide compounds for dementia
AU2008251557B2 (en) * 2007-05-10 2012-12-06 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20090048229A1 (en) * 2007-07-18 2009-02-19 Rupniak Nadia M J Methods for promoting wakefulness
ES2421237T7 (en) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Imidazo [1,2-a] pyridine derivatives as modulators of the serotonergic 5ht2a receptor in the treatment of disorders related thereto
WO2009039313A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
CA2701620C (en) 2007-10-05 2014-12-09 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
EP2095828A1 (en) * 2008-02-29 2009-09-02 Gnosis S.p.A. Use of S-adenosylmethionine (SAM) and superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzeimer's disease
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20110056863A1 (en) * 2008-05-30 2011-03-10 Junichi Sekiya Adhesive preparation containing donepezil, and package of the same
CN102046171B (en) * 2008-05-30 2013-06-19 日东电工株式会社 Transdermal preparation
JP5734853B2 (en) * 2008-08-29 2015-06-17 トレヴェンティス コーポレイションTreventis Corporation Butyrylcholinesterase ligand as a diagnostic tool and therapy for nervous system diseases
SI2364142T1 (en) 2008-10-28 2018-06-29 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP2445877B1 (en) 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
WO2010088827A1 (en) * 2009-02-06 2010-08-12 上海交通大学医学院 Novel uses of huperzine a and ophthalmic preparations thereof
WO2010117727A2 (en) * 2009-03-30 2010-10-14 The General Hospital Corporation Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
US10206921B2 (en) * 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011039675A2 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine transdermal therapeutic dosage forms
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
EP3132793A1 (en) 2009-12-02 2017-02-22 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
GR1007368B (en) * 2010-05-27 2011-08-02 Alapis Α.Β.Ε.Ε., Drinkable pharmaceutical solutions for the treatment of dementia symptoms
US9345696B2 (en) * 2010-11-12 2016-05-24 The Children's Medical Center Corporation Methods for treating nicotinic acetylcholine receptor associated diseases
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
WO2012164563A1 (en) * 2011-06-01 2012-12-06 Brain Watch Ltd. Isotopically labeled cdp-choline and uses thereof
NZ623046A (en) * 2011-10-27 2015-12-24 Proteotech Inc Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
AU2013312240A1 (en) * 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10238673B2 (en) * 2013-03-13 2019-03-26 Genetic Disease Investigators, LLC Methods and compositions for treatment of dry eye and correction of organ dysfunctions
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
ES2700541T3 (en) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, its preparation and use
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US20150013695A1 (en) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US20150086616A1 (en) * 2013-09-20 2015-03-26 Steven Lehrer Method for the prevention and treatment of alzheimer's disease
WO2015127556A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating defecation in a patient in need thereof
WO2015127558A1 (en) * 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
CN106794364B (en) 2014-04-30 2019-12-24 哥伦比亚大学董事会 Substituted 4-phenylpiperidines, their preparation and use
CA2961936A1 (en) * 2014-10-03 2016-04-07 Lachesis Biosciences Pty Ltd Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
WO2016109480A1 (en) 2014-12-30 2016-07-07 Forma Therapeutics, Inc. Pyrrolotriazinone and imidazotriazinone derivatives as ubiquitin-specific protease 7 (usp7) inhibitors for the treatment of cancer
AR103297A1 (en) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pyrrolo and pyrazolopyrimidines as protease inhibitors specific ubiquitin 7
JP2018504431A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス,インコーポレイテッド Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor
WO2016126935A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
CN107810002A (en) 2015-05-22 2018-03-16 艾吉因生物股份有限公司 The extended release drugs composition of Levetiracetam
RU2017145976A (en) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Diaryl- and arylheteroarylurea derivatives applicable for the prevention and treatment of behavioral disturbances during the REM phase of sleep
TW201720439A (en) 2015-07-15 2017-06-16 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
EP3334425A1 (en) * 2015-08-14 2018-06-20 QR Pharma Methods of treatment or prevention of acute brain or nerve injuries
CA3017787A1 (en) * 2016-03-15 2017-09-21 University Of The Sciences Compositions and methods for treating compulsive-like behavior in a subject
KR101838430B1 (en) 2017-01-23 2018-03-13 경희대학교 산학협력단 Compositions comprising ibuprofen for preventing or treating post traumatic stress disorder

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956391A (en) * 1988-08-17 1990-09-11 Sapse Alfred T Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and alzheimer's disease
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
ES2190472T5 (en) * 1995-06-07 2012-03-09 Ortho-Mcneil Pharmaceutical, Inc. Transdermal patch for the administration of 17-deacetil norgestimato, in combination with a strogen.
IT1282736B1 (en) * 1996-05-21 1998-03-31 Angelini Ricerche Spa Use of derivatives of p-aminophenol to prepare pharmaceutical compositions useful in the treatment of neurodegenerative diseases
US5981549A (en) * 1997-02-14 1999-11-09 Synapse Pharmaceutical International Method for controlling or alleviating the symptoms of respiratory disease and allergies
NZ337515A (en) * 1997-03-03 2002-07-26 Eisai Co Ltd Use of cholinesterase inhibitors to treat disorders of attention
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
TWI233810B (en) * 1999-02-19 2005-06-11 Hisamitsu Pharmaceutical Co A paster sheet
US7023833B1 (en) * 1999-09-10 2006-04-04 Pulse-Link, Inc. Baseband wireless network for isochronous communication
US6640213B1 (en) * 1999-12-13 2003-10-28 Tenley Anne Carp Automated process for conducting jury voir dire
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6294999B1 (en) * 1999-12-29 2001-09-25 Becton, Dickinson And Company Systems and methods for monitoring patient compliance with medication regimens
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
DE60124730T2 (en) * 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. New methods using cholinesteraseinhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1217347A3 (en) * 2000-12-21 2004-02-11 Zeiss Optronik GmbH Radiation detector with active optical protection system
SI20848A (en) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Pharmaceutical formulation containing atorvastatin calcium
WO2003024450A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
AU2002340232A1 (en) * 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
US20040018458A1 (en) * 2002-05-17 2004-01-29 Hajime Nakagawa Photothermographic material
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EA008863B1 (en) * 2002-10-24 2007-08-31 Мерц Фарма Гмбх Унд Ко. Кгаа Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
JP5666087B2 (en) * 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Methods and compositions for the treatment of CNS related diseases
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug

Also Published As

Publication number Publication date
AU2003298514A8 (en) 2004-05-04
US20110053981A1 (en) 2011-03-03
TW200401649A (en) 2004-02-01
US20060018839A1 (en) 2006-01-26
WO2004034963A3 (en) 2004-07-22
US20090042939A1 (en) 2009-02-12
WO2004034963A2 (en) 2004-04-29
US20080167343A1 (en) 2008-07-10
US20090042940A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
AP2089A (en) Compositions and methods for combination antiviraltherapy
AP2421A (en) Quinoline derivatives and their use as mycobacterial inhibitors.
EP1551372B8 (en) Sequestering subunit and related compositions and methods
AU2002220195A1 (en) Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
AU2003277103A1 (en) Creamer compositions and methods of making and using the same
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003270593A1 (en) Devices and methods for improving vision
AU2003298712A1 (en) Methods and compositions for applying pharmacologic agents to the ear
AU2003218293A1 (en) Tripod and method
AU2003243718A1 (en) Epidural anesthesia kit and method
AU2003237884A1 (en) Method and device for anastomoses
AU2003224728A1 (en) Dynamic player management
AU2003224971A1 (en) Tissue fastening devices and related insertion tools and methods
AU2003265349A1 (en) Pyrrolotriazine kinase inhibitors
EP1311272A4 (en) Novel methods using cholinesterase inhibitors
AU2002250394A1 (en) Rho-kinase inhibitors
AU2003286711A1 (en) Indazolinone compositions useful as kinase inhibitors
AU2003284352A1 (en) Pentafluoropropene-based compositions
AU2002245709A1 (en) Rho-kinase inhibitors
EP1539180A4 (en) Compounds, compositions, and methods
ZA200406467B (en) N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as DDP-IV inhibitors.
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003205950A1 (en) Placement of alternative advertisements
AU2003265242A8 (en) Compounds, compositions, and methods
AU2003253664A1 (en) Compositions and methods for reducing lung volume

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase